HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Effects of different antigenic stimuli on thymic function and interleukin-7/CD127 system in patients with chronic HIV infection.

AbstractBACKGROUND:
We tested if an increase in immune activation and a decrease in CD4⁺ T cells induced by different antigenic stimuli could be associated with changes in the thymic function and the interleukin (IL)-7/CD127 system.
METHODS:
Twenty-six HIV-infected patients under combined antiretroviral therapy (cART) were randomized to receive, during 12 months, a complete immunization schedule (7 vaccines and 15 doses) or placebo. Thereafter, cART was interrupted during 6 months. Changes in the thymic function and the IL-7/CD127 system after 3 different antigenic stimuli (vaccines, episodes of low-level intermittent viremia before cART interruption, or viral load rebound after cART interruption) were assessed.
RESULTS:
During the period on cART, neither vaccines nor low-level viremia influenced thymic function or IL-7/CD127 system parameters. By analyzing the cohort as a whole while on cART, a significant improvement was observed in the thymic function as measured by an increase in the thymic volume (P = 0.024), T-cell receptor excision circle-bearing cells (P = 0.012), and naive CD4⁺ and CD8⁺ T cells (P = 0.069 both). No significant changes were observed in the IL-7/CD127 system. After cART interruption, a decrease in T-cell receptor excision circles (P < 0.001) and naive CD8⁺ T cells (P < 0.001), an increase in IL-7 and expression of CD127 on naive and memory CD4⁺ T cells (P = 0.028, P = 0.088, and P = 0.04, respectively), and a significant decrease in CD127 on naive and memory CD8⁺ T cells (P = 0.01, P = 0.006, respectively) were observed.
CONCLUSIONS:
Low-level transient antigenic stimuli during cART were not associated with changes in the thymic function or the IL-7/CD127 system. Conversely, viral load rebound very early after cART interruption influenced the thymic function and the IL-7/CD127 system. Clinical Trials.gov number NCT00329251.
AuthorsPedro Castro, Berta Torres, Anna López, Raquel González, Anna Vilella, Jose M Nicolas, Teresa Gallart, Tomàs Pumarola, Marcelo Sánchez, Manuel Leal, Alejandro Vallejo, José M Bayas, José M Gatell, Montserrat Plana, Felipe García
JournalJournal of acquired immune deficiency syndromes (1999) (J Acquir Immune Defic Syndr) Vol. 66 Issue 5 Pg. 466-72 (Aug 15 2014) ISSN: 1944-7884 [Electronic] United States
PMID24820104 (Publication Type: Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
Chemical References
  • AIDS Vaccines
  • Anti-HIV Agents
  • IL7 protein, human
  • Interleukin-7
  • Receptors, Interleukin-7
Topics
  • AIDS Vaccines
  • Adult
  • Anti-HIV Agents
  • CD4 Lymphocyte Count
  • Chronic Disease
  • Cohort Studies
  • Double-Blind Method
  • Female
  • Gene Expression Regulation (immunology)
  • HIV Infections (immunology, metabolism)
  • Humans
  • Interleukin-7 (genetics, metabolism)
  • Male
  • Middle Aged
  • Receptors, Interleukin-7 (genetics, metabolism)
  • Risk Factors
  • Thymus Gland (physiology)
  • Viral Load
  • Viremia

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: